Osimertinib (Clinical Trials and Efficacy)
- FLAURA Trial: A pivotal Phase III clinical trial that demonstrated osimertinib’s superiority over first-generation EGFR TKIs in terms of progression-free survival (PFS) and overall survival (OS) in the first-line setting.
- AURA3 Trial: This trial showed significant improvement in PFS for patients with T790M-positive NSCLC treated with osimertinib compared to those treated with platinum-based chemotherapy